M2 Pharma - Therapy Areas - Cardiovascular

CellPoint plans to start patient recruitment for Phase 2b cardiovascular imaging study of Oncardia kits

20 May 2019 - CellPoint, a biopharmaceutical company, announced on Friday that it plans to commence patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronar...

Exelixis' Collaborator Daiichi Sankyo Launches Minnebro Tablets in Japan

17 May 2019 - - US-based biotechnology company Exelixis, Inc.'s (NASDAQ: EXEL) partner, Japan-based Daiichi Sankyo Company, Ltd. has launched Minnebro (esaxerenone) tablets as a treatment for pat...

Moderna Publishes Phase 1 Data for mRNA Vaccines Against Two Potential Pandemic Influenza Strains

16 May 2019 - - Results from two Phase 1 clinical studies have been published showing that mRNA vaccines against H10N8 and H7N9 influenza viruses were well-tolerated and elicited robust immune respons...

Rob Abrams joins Evolve as partner

15 May 2019 - Medical device development company Evolve Medtech Partners announced on Wednesday that Rob Abrams has joined the company's team.With more than 30 years of experience in biomedical d...

Akebia Therapeutics Reports Full Enrollment of Phase 3 INNO2VATE Studies

15 May 2019 - - US-based biopharmaceutical company Akebia Therapeutics, Inc. (NASDAQ: AKBA) has completed
full enrollment of its global Phase 3 INNO2VATE studies for vadadustat, the company said...

Verve Therapeutics Founded to Protect Against Heart Disease Launches with USD 58.5m in Series A Funding Led by GV

10 May 2019 - - US-based cardiovascular company Verve Therapeutics has been launched to discover and develop therapies that safely edit the adult human genome to permanently reduce a person's ris...